Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 7/20 | 0.38 |
| ▸ | CDC25B | P30305 | 7/20 | 0.38 |
| ▸ | CDC25C | P30307 | 6/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimbrolide SCHEMBL13668734 | 1.00 | CDC25A (0.38) | CDC25ACDC25BCDC25CALOX5TRPA1 | |
| Fimbrolide SCHEMBL1049932 | 1.00 | CDC25A (0.38) | CDC25ACDC25BCDC25CALOX5TRPA1 | |
| SCHEMBL6331065 | 0.93 | CDC25A (0.46) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL6331066 | 0.93 | CDC25A (0.46) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4651384 | 0.86 | CDC25A (0.35) | CDC25ACDC25BCDC25CALOX5TRPA1 | |
| SCHEMBL18196022 | 0.86 | CDC25A (0.38) | CDC25ACDC25BCDC25CALOX5TRPA1 | |
| SCHEMBL4651386 | 0.86 | CDC25A (0.35) | CDC25ACDC25BCDC25CALOX5TRPA1 | |
| SCHEMBL6945436 | 0.81 | LMNA (0.34) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4650435 | 0.80 | CDC25A (0.43) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4650432 | 0.80 | CDC25A (0.43) | CDC25ACDC25BCDC25CALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283130-B1 | Dispersin B(TM), 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof | KANE BIOTECH INC (CA) | 2014-09-10 | — | — | EP | claimed |
| US-20120157522-A1 | B. Anthracis Prevention and Treatment: Mutant B. Anthracis Lacking Luxs Activity and Furanone Inhibition of Growth, AI-2 Quorum Sensing, and Toxin Production | UNIVERSITY OF CONNECTICUT (US) | 2012-06-21 | — | — | US | claimed |
| US-20080299153-A1 | B. ANTHRACIS PREVENTION AND TREATMENT: MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION | NEW YORK UNIVERSITY (US) | 2008-12-04 | — | — | US | claimed |
| US-20050042634-A1 | B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production | UNIVERSITY OF CONNECTICUT | 2005-02-24 | — | — | US | claimed |
| WO-2005005598-A2 | B. ANTHRACIS LUXS AND FURANONE INHIBITION OF A1-2 QUORUM SENSING | NEW YORK UNIVERSITY (US) | 2005-01-20 | — | — | WO | claimed |
| US-6692557-B1 | ISOTHIAZOLONE OR FURANONE IN SHELLAC, LATEX, CASEIN, WAX, OR HYDROGEL POLYMER NONTOXIC CARRIER | UNISEARCH LIMITED (AU) | 2004-02-17 | — | — | US | claimed |
| US-12083159-B2 | Antibacterial compositions, methods of making and use thereof | MOREHOUSE SCHOOL OF MEDICINE (US) | 2024-09-10 | — | — | US | disclosed |
| US-12083158-B2 | Antibacterial compositions, methods of making and use thereof | MOREHOUSE SCHOOL OF MEDICINE (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3801029-B1 | ANTIBACTERIAL COMPOSITIONS, METHODS OF MAKING AND USE THEREOF | MOREHOUSE SCHOOL OF MEDICINE (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2022087052-A1 | INFLAMMATION REDUCING COMPOSITION CONTAINING A CANNABIS SATIVA COMPOUND | HAUGHT JOHN CHRISTIAN (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220125696-A1 | INFLAMMATION REDUCING COMPOSITION CONTAINING A CANNABIS SATIVA COMPOUND | HAUGHT JOHN CHRISTIAN (US) | 2022-04-28 | — | — | US | disclosed |
| US-20200197483-A1 | ANTIBACTERIAL COMPOSITIONS, METHODS OF MAKING AND USE THEREOF | MOREHOUSE SCHOOL OF MEDICINE | 2020-06-25 | — | — | US | disclosed |
| US-20190134151-A1 | ANTIBACTERIAL COMPOSITIONS, METHODS OF MAKING AND USE THEREOF | MOREHOUSE SCHOOL OF MEDICINE | 2019-05-09 | — | — | US | disclosed |
| US-6692557-B1 | ISOTHIAZOLONE OR FURANONE IN SHELLAC, LATEX, CASEIN, WAX, OR HYDROGEL POLYMER NONTOXIC CARRIER | UNISEARCH LIMITED (AU) | 2004-02-17 | — | — | US | disclosed |
| US-6635692-B1 | Antifouling polymers | AQUACULTURE CRC LIMITED (AU) | 2003-10-21 | — | — | US | disclosed |
| EP-0998533-A4 | ANTIFOULING OF SHELLFISH AND AQUACULTURE APPARATUS | AQUACULTURE CRC LIMITED (AU) | 2000-11-02 | — | — | EP | disclosed |
| EP-0998533-A1 | ANTIFOULING OF SHELLFISH AND AQUACULTURE APPARATUS | Aquaculture CRC Limited (AU) | 2000-05-10 | — | — | EP | disclosed |
| EP-0996681-A1 | ANTIFOULING POLYMERS | Aquaculture CRC Limited (AU) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999005227-A1 | ANTIFOULING OF SHELLFISH AND AQUACULTURE APPARATUS | AQUACULTURE CRC LIMITED (AU) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999001514-A1 | ANTIFOULING POLYMERS | AQUACULTURE CRC LIMITED (AU) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157522-A1 | B. Anthracis Prevention and Treatment: Mutant B. Anthracis Lacking Luxs Activity and Furanone Inhibition of Growth, AI-2 Quorum Sensing, and Toxin Production | ANTXR2, FPR2, ING2 | CDC25A 1505/4885CDC25B 587/4885CDC25C 1342/4885 |
| US-20080299153-A1 | B. ANTHRACIS PREVENTION AND TREATMENT: MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION | ANTXR2, FPR2, ING2 | CDC25A 1505/4885CDC25B 587/4885CDC25C 1342/4885 |
| US-20050042634-A1 | B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production | ANTXR2, FPR2, ING2 | CDC25A 1505/4885CDC25B 587/4885CDC25C 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.